chst11 Antibody

What is CHST11 and where is it primarily expressed?

CHST11 (Carbohydrate Chondroitin 4 Sulfotransferase 11) functions as an enzyme that catalyzes the transfer of sulfate groups to chondroitin. Immunohistochemical analysis reveals that CHST11 protein is mainly localized in the cytoplasm of cells. The enzyme plays important roles in cellular signaling pathways and extracellular matrix organization. In pathological contexts, CHST11 has been identified as significantly upregulated in multiple cancer types, including hepatocellular carcinoma, as demonstrated through comprehensive multi-center analyses involving over 3,000 HCC samples compared to normal tissues .

What types of CHST11 antibodies are available for research?

Research-grade CHST11 antibodies are available in several formats:

• Host species: Primarily rabbit polyclonal and mouse monoclonal antibodies

• Target epitopes: Multiple options targeting different amino acid regions (e.g., AA 214-330, AA 230-337)

• Conjugation options: Unconjugated, FITC-conjugated, and HRP-conjugated variants

• Applications: Antibodies validated for ELISA, Western Blot, and Immunohistochemistry

• Species reactivity: Options for human-specific detection or broader cross-reactivity with multiple species

What experimental applications are validated for CHST11 antibodies?

CHST11 antibodies have been validated for:

• Immunohistochemistry (IHC): Typically used at 1:100 dilution for formalin-fixed paraffin-embedded tissues with cytoplasmic staining patterns. Scoring systems like immunoreactive scores (IRS) can be implemented for semi-quantitative assessment, with IRS >6 considered high expression .

• ELISA: For quantitative detection of CHST11 in solution-based samples, with protein G-purified antibodies showing >95% purity .

• Western Blot: For detecting CHST11 protein expression in cell lysates and tissue homogenates, often used in conjunction with gene silencing experiments to confirm specificity .

How does CHST11 expression correlate with prognosis in hepatocellular carcinoma?

CHST11 serves as an independent prognostic biomarker in HCC with significant clinical implications:

Prognostic value analysis:

Clinical correlation:

• TNM staging: Patients with TNM stage III-IV exhibit significantly higher CHST11 mRNA expression than those with TNM stage I-II (p = 0.0304)

• TP53 mutation: CHST11 mRNA is significantly overexpressed in mutated TP53 group compared to wild-type TP53 group (p < 0.0001)

What is the relationship between CHST11 and tumor immune microenvironment?

CHST11 plays a critical role in shaping the tumor immune microenvironment in HCC:

Immune infiltration correlation:

• Patients with increased CHST11 expression demonstrate higher immune scores (p < 0.0001) and stromal scores (p < 0.0001)

• CHST11 expression positively correlates with regulatory T cell (Treg) infiltration, validated through multiple computational approaches:

  • CIBERSORT: R = 0.163, p = 0.002

  • CIBERSORT-ABS: R = 0.383, p < 0.0001

  • Quantiseq: R = 0.466, p < 0.0001

Immune checkpoint regulation:

• CHST11 expression positively correlates with Treg cell markers (FOXP3, CTLA4, ICOS, LAG3, TIGIT)

• CHST11 expression significantly correlates with immune checkpoints PD-L1 and PD-1

• KEGG pathway analysis reveals CHST11 participation in PD-L1/PD-1 checkpoint pathway through regulation of multiple genes (TICAM2, LAT, TLR2, CD4, STAT3, NFKBIE, CD3D)

How do functional studies validate CHST11's role in cancer progression?

Experimental manipulation of CHST11 expression reveals its functional significance:

Knockdown experiments:

• CHST11 expression was significantly reduced in Huh7 and Hep3B liver cancer cells using lentiviral vectors (si-81566 and si-81567)

• Cell proliferation rates were markedly decreased in CHST11-silenced groups compared to vector controls

• Wound healing assays demonstrated reduced migration capacity in CHST11-knockdown cells

Pathway analysis:

• Functional enrichment analysis of CHST11-associated genes revealed involvement in:

  • Cell proliferation: "nuclear division," "cell cycle checkpoint," "cell cycle"

  • Metastasis: "extracellular matrix structural constituent"

  • Immune regulation: "T cell activation," "T cell differentiation," "PD-L1 expression and PD-1 checkpoint pathway"

• Gene Set Enrichment Analysis (GSEA) showed that high CHST11 expression positively regulates cell-cell adhesion, focal adhesion, and immune response activation

What methodological considerations are important when using CHST11 antibodies for immunohistochemistry?

For optimal IHC results with CHST11 antibodies, researchers should consider:

Protocol optimization:

• Antibody dilution: 1:100 has been validated for rabbit polyclonal CHST11 antibodies from commercial sources

• Detection system: DAB (3,3'-diaminobenzidine) or equivalent chromogenic substrate

• Counterstaining: Hematoxylin for nuclear visualization

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0)

Scoring methodology:

• Assessment parameters: Staining intensity and percentage of positive cells

• Field selection: 10 consecutive and representative fields at 400× magnification

• Scoring system: Immunoreactive scores (IRS) with defined threshold (IRS >6 considered high expression)

• Evaluator concordance: Independent assessment by multiple pathologists to ensure reliability

How can CHST11 be targeted in combination cancer immunotherapy strategies?

Based on functional and correlative studies, CHST11 represents a potential target for innovative immunotherapy approaches:

Therapeutic rationale:

• CHST11 knockdown inhibits cancer cell proliferation and metastasis

• CHST11 expression facilitates regulatory T cell infiltration

• CHST11 promotes expression of immune checkpoints PD-L1/PD-1

• High CHST11 correlates with immunosuppression in HCC

Potential combination strategies:

• CHST11 inhibition combined with PD-L1/PD-1 checkpoint blockade

• Targeting CHST11 to reduce Tregs infiltration while simultaneously applying immune checkpoint inhibitors

• Developing small molecule inhibitors or targeted antibodies against CHST11 as novel immunomodulatory agents

What controls should be included when validating CHST11 antibodies?

For rigorous antibody validation, researchers should incorporate:

Positive controls:

• Cell lines with known CHST11 expression (based on mRNA data)

• Tissues with validated CHST11 expression (e.g., HCC samples with confirmed high expression)

• Recombinant CHST11 protein standards for Western blot or ELISA

Negative controls:

• CHST11 knockdown or knockout cells/tissues

• Isotype control antibodies to assess non-specific binding

• Peptide blocking experiments using immunizing peptide

Application-specific controls:

• For IHC: Omission of primary antibody while maintaining all other steps

• For Western blot: Size verification with molecular weight markers

• For immunoprecipitation: Non-specific IgG control

How should researchers interpret contradictory CHST11 expression data?

When faced with contradictory results regarding CHST11 expression:

Technical verification:

• Confirm antibody specificity through knockout/knockdown validation

• Verify antibody lot consistency and storage conditions

• Assess potential cross-reactivity with related sulfotransferases

Methodological reconciliation:

• Compare RNA vs. protein expression levels (potential post-transcriptional regulation)

• Evaluate subcellular localization differences (cytoplasmic vs. other compartments)

• Consider heterogeneity within samples (tumor vs. stromal areas)

Contextual analysis:

• Examine relationship with clinicopathological parameters

• Consider disease stage or subtype variations

• Integrate data from multiple detection methods (IHC, Western blot, RT-qPCR)

What experimental approaches best demonstrate the functional impact of CHST11 in cancer models?

To establish CHST11's functional significance, researchers should consider:

In vitro approaches:

• Gene silencing using validated siRNA or shRNA constructs

• CRISPR/Cas9-mediated knockout models

• Overexpression systems in low-expressing cell lines

• Functional assays: proliferation, migration, invasion, apoptosis

In vivo models:

• Xenograft models with CHST11-modulated cell lines

• Measurement of tumor growth kinetics and metastatic capacity

• Immune infiltration analysis in immunocompetent models

• Response to immunotherapy in CHST11-modulated tumors

Mechanistic studies:

• Pathway analysis through phosphoprotein arrays

• Chromatin immunoprecipitation to identify transcriptional targets

• Co-immunoprecipitation to identify protein-protein interactions

• Glycosaminoglycan profiling to assess enzymatic function

How should transcriptomic and proteomic CHST11 data be integrated for comprehensive analysis?

For integrative analysis of CHST11 across platforms:

Multi-omics approach:

• Correlate mRNA expression with protein levels in matched samples

• Identify post-transcriptional regulation mechanisms (miRNAs, RNA-binding proteins)

• Integrate with glycomic data to connect CHST11 enzymatic activity with substrate modification

Computational integration:

• Apply machine learning algorithms to identify patterns across platforms

• Develop predictive models incorporating multiple data types

• Conduct network analysis to identify CHST11-associated functional modules

Functional validation:

• Confirm key findings from computational analysis through targeted experiments

• Use isogenic cell lines with CHST11 modification to validate predictions

• Apply chemical inhibitors to simulate therapeutic targeting scenarios

What considerations should guide research into CHST11 as a therapeutic target?

Development of CHST11-targeted therapeutics requires:

Target validation:

• Confirmation of differential expression in cancer vs. normal tissues

• Demonstration of functional dependency through genetic manipulation

• Validation in multiple relevant cancer models and patient-derived samples

Compound development:

• Structure-based design of small molecule inhibitors of CHST11 enzymatic activity

• Development of neutralizing antibodies against extracellular or secreted CHST11

• Assessment of specificity against other sulfotransferase family members

Therapeutic combination strategy:

• Evaluation alongside immune checkpoint inhibitors (anti-PD-1/PD-L1)

• Combination with Treg-depleting agents

• Integration with conventional therapies (chemotherapy, radiotherapy)

• Biomarker development for patient stratification based on CHST11 expression patterns

What criteria should guide selection between polyclonal and monoclonal CHST11 antibodies?

The choice between antibody formats depends on research objectives:

Polyclonal antibodies advantages:

• Recognition of multiple epitopes increases detection sensitivity

• Greater tolerance to minor protein denaturation or modifications

• Usually less expensive and simpler production process

• Better for applications where maximum antigen capture is desired

Monoclonal antibodies advantages:

• Consistent lot-to-lot reproducibility

• Higher specificity for a single epitope

• Reduced background and cross-reactivity

• Superior for applications requiring precise epitope targeting

• Essential for therapeutic development pipelines

What specific epitope considerations apply when selecting CHST11 antibodies?

When choosing among available CHST11 antibody epitopes:

Functional domain targeting:

• Antibodies against catalytic domains may interfere with enzymatic activity

• Regulatory domain antibodies might detect activation-dependent conformations

• N-terminal vs. C-terminal epitopes may reveal processing or degradation products

Application suitability:

• Linear epitopes (e.g., AA 214-330) often perform better in denatured applications like Western blot

• Conformational epitopes may be preferable for applications using native protein (immunoprecipitation, flow cytometry)

• Consider epitope conservation when working with different species